Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

Alumis shares climb after its psoriasis drug met all late-stage trial goals, showing strong skin clearance, fast results, and ...

Alumis (ALMS) shares climbed nearly 150% on Tuesday after the autoimmune disease drug developer said its lead candidate, ...

Shares of Alumis ALMS surged 95.3% on Jan. 6, after the company announced positive top-line data from its two phase III ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met their co-primary endpoints in adults with moderate to severe plaque ...

Investing.com -- Alumis Inc. (NASDAQ:ALMS) stock surged 60% Tuesday after the company reported positive Phase 3 trial results for its psoriasis drug envudeucitinib, showing superior skin clearance ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Shares of Alumis surged after the company said both of its phase three trials of its envudeucitinib drug for moderate-to-severe plaque psoriasis met all primary and secondary endpoints. The stock more ...

Khaberni - A medical study has revealed promising results in treating moderate to severe psoriasis, one of the most ...

Cosentyx (secukinumab) is a brand-name drug that’s prescribed for certain conditions, including plaque psoriasis and psoriatic arthritis. This article covers topics such as side effects, dosage, and ...

I have had psoriasis for about 15 years and I am going into hospital shortly for treatment. They are going to give me tablets and said I will be in for about two weeks because there may be side ...